Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 7/2015

01-07-2015 | Original Article

Osteopontin: a potential biomarker of Gaucher disease

Authors: Filippo Vairo, Fernanda Sperb-Ludwig, Matheus Wilke, Kristiane Michellin-Tirelli, Cristina Netto, Eurico Camargo Neto, Ida Schwartz

Published in: Annals of Hematology | Issue 7/2015

Login to get access

Abstract

Gaucher disease (GD) is one of the most prevalent lysosomal storage disorders and the disorder that has the greatest immune system involvement. Pathologic lipid accumulation in macrophages accounts for a small amount of the additional tissue mass in the liver and spleen. The additional increase may be related to an inflammatory response because Gaucher cells secrete inflammatory mediators. Osteopontin (OPN) is a protein identified in cancer cells and in bone cells that is produced by several types of immune cells including T-cells and macrophages. We report here elevated OPN levels in the plasma of type 1 GD patients and its sensitive response to enzyme replacement therapy. The mean OPN value of GD patients receiving ERT was similar to the values of controls and patients with other lysosomal disorders. When comparing untreated and treated GD patients, the p value was <0.001. In GD, OPN appears to be more sensitive to ERT than chitotriosidase and can be used during the follow-up of patients who are chitotriosidase deficient. Additional extended studies are required to relate variations in the OPN levels to clinical findings and response to therapy in GD patients.
Literature
1.
Meikle PJ, Hopwood JJ (2003) Lysosomal storage disorders: emerging therapeutic options require early diagnosis. Eur J Pediatr 162(Suppl 1):S34–S37CrossRefPubMed
2.
Mistry PK, Cappellini MD, Lukina E, Ozsan H, Mach Pascual S, Rosenbaum H et al (2011) A reappraisal of Gaucher disease-diagnosis and disease management algorithms. Am J Hematol 86(1):110–115CrossRefPubMedCentralPubMed
3.
Beutler E (2006) Gaucher disease: multiple lessons from a single gene disorder. Acta Paediatr Suppl 95(451):103–109CrossRefPubMed
4.
Jmoudiak M, Futerman AH (2005) Gaucher disease: pathological mechanisms and modern management. Br J Haematol 129(2):178–188CrossRefPubMed
5.
Hughes DA, Pastores GM (2010) The pathophysiology of GD - current understanding and rationale for existing and emerging therapeutic approaches. Wien Med Wochenschr 160(23–24):594–599CrossRefPubMed
6.
Boven LA, van Meurs M, Boot RG, Mehta A, Boon L, Aerts JM et al (2004) Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol 122(3):359–369CrossRefPubMed
7.
Ron I, Horowitz M (2005) ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum Mol Genet 14(16):2387–2398CrossRefPubMed
8.
Pelled D, Trajkovic-Bodennec S, Lloyd-Evans E, Sidransky E, Schiffmann R, Futerman AH (2005) Enhanced calcium release in the acute neuronopathic form of Gaucher disease. Neurobiol Dis 18(1):83–88CrossRefPubMed
9.
Deganuto M, Pittis MG, Pines A, Dominissini S, Kelley MR, Garcia R et al (2007) Altered intracellular redox status in Gaucher disease fibroblasts and impairment of adaptive response against oxidative stress. J Cell Physiol 212(1):223–235CrossRefPubMed
10.
Sun Y, Grabowski GA (2010) Impaired autophagosomes and lysosomes in neuronopathic Gaucher disease. Autophagy 6(5):648–649CrossRefPubMed
11.
Cox TM (2001) Gaucher disease: understanding the molecular pathogenesis of sphingolipidoses. J Inherit Metab Dis 24(Suppl 2):106–121, discussion 87-8PubMed
12.
Moran MT, Schofield JP, Hayman AR, Shi GP, Young E, Cox TM (2000) Pathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin K. Blood 96(5):1969–1978PubMed
13.
Hollak CE, Evers L, Aerts JM, van Oers MH (1997) Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol Dis 23(2):201–212CrossRefPubMed
14.
Pavlova EV, Deegan PB, Tindall J, McFarlane I, Mehta A, Hughes D et al (2011) Potential biomarkers of osteonecrosis in Gaucher disease. Blood Cells Mol Dis 46(1):27–33CrossRefPubMed
15.
Aerts JM, Hollak CE (1997) Plasma and metabolic abnormalities in Gaucher’s disease. Bailliere’s Clin Haematol 10(4):691–709CrossRef
16.
Hollak CE, van Weely S, van Oers MH, Aerts JM (1994) Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Investig 93(3):1288–1292CrossRefPubMedCentralPubMed
17.
Boot RG, Verhoek M, de Fost M, Hollak CE, Maas M, Bleijlevens B et al (2004) Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 103(1):33–39CrossRefPubMed
18.
Dekker N, van Dussen L, Hollak CE, Overkleeft H, Scheij S, Ghauharali K et al (2011) Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood 118(16):e118–e127CrossRefPubMedCentralPubMed
19.
Rolfs A, Giese AK, Grittner U, Mascher D, Elstein D, Zimran A et al (2013) Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients. PLoS One 8(11):e79732CrossRefPubMedCentralPubMed
20.
Senger DR, Perruzzi CA, Papadopoulos A, Tenen DG (1989) Purification of a human milk protein closely similar to tumor-secreted phosphoproteins and osteopontin. Biochim Biophys Acta 996(1–2):43–48CrossRefPubMed
21.
Oldberg A, Franzen A, Heinegard D (1986) Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci U S A 83(23):8819–8823CrossRefPubMedCentralPubMed
22.
Weber GF, Cantor H (1996) The immunology of Eta-1/osteopontin. Cytokine Growth Factor Rev 7(3):241–248CrossRefPubMed
23.
24.
Ramaiah SK, Rittling S (2008) Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol Sci : Off J Soc Toxicol 103(1):4–13CrossRef
25.
Atkins K, Berry JE, Zhang WZ, Harris JF, Chambers AF, Simpson RU et al (1998) Coordinate expression of OPN and associated receptors during monocyte/macrophage differentiation of HL-60 cells. J Cell Physiol 175(2):229–237CrossRefPubMed
26.
Konno S, Eckman JA, Plunkett B, Li X, Berman JS, Schroeder J et al (2006) Interleukin-10 and Th2 cytokines differentially regulate osteopontin expression in human monocytes and dendritic cells. J Interf Cytokine Res : Off J Int Soc Interferon and Cytokine Res 26(8):562–567CrossRef
27.
Li X, O’Regan AW, Berman JS (2003) IFN-gamma induction of osteopontin expression in human monocytoid cells. J Interf Cytokine Res : Off J Int Soc Interferon and Cytokine Res 23(5):259–265CrossRef
28.
Rollo EE, Denhardt DT (1996) Differential effects of osteopontin on the cytotoxic activity of macrophages from young and old mice. Immunology 88(4):642–647CrossRefPubMedCentralPubMed
29.
O’Regan AW, Hayden JM, Berman JS (2000) Osteopontin augments CD3-mediated interferon-gamma and CD40 ligand expression by T cells, which results in IL-12 production from peripheral blood mononuclear cells. J Leukoc Biol 68(4):495–502PubMed
30.
Zheng W, Li R, Pan H, He D, Xu R, Guo TB et al (2009) Role of osteopontin in induction of monocyte chemoattractant protein 1 and macrophage inflammatory protein 1beta through the NF-kappaB and MAPK pathways in rheumatoid arthritis. Arthritis Rheum 60(7):1957–1965CrossRefPubMed
31.
Nystrom T, Duner P, Hultgardh-Nilsson A (2007) A constitutive endogenous osteopontin production is important for macrophage function and differentiation. Exp Cell Res 313(6):1149–1160CrossRefPubMed
32.
Giachelli CM, Lombardi D, Johnson RJ, Murry CE, Almeida M (1998) Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am J Pathol 152(2):353–358PubMedCentralPubMed
33.
Bourassa B, Monaghan S, Rittling SR (2004) Impaired anti-tumor cytotoxicity of macrophages from osteopontin-deficient mice. Cell Immunol 227(1):1–11CrossRefPubMed
34.
Pedraza CE, Nikolcheva LG, Kaartinen MT, Barralet JE, McKee MD (2008) Osteopontin functions as an opsonin and facilitates phagocytosis by macrophages of hydroxyapatite-coated microspheres: implications for bone wound healing. Bone 43(4):708–716CrossRefPubMed
35.
Vedder AC, Cox-Brinkman J, Hollak CE, Linthorst GE, Groener JE, Helmond MT et al (2006) Plasma chitotriosidase in male Fabry patients: a marker for monitoring lipid-laden macrophages and their correction by enzyme replacement therapy. Mol Genet Metab 89(3):239–244CrossRefPubMed
36.
Dornelles AD, de Oliveira Netto CB, Vairo F, de Mari JF, Tirelli KM, Schwartz IV (2014) Breastfeeding in Gaucher disease: is enzyme replacement therapy safe? Clin Ther 36(6):990–991CrossRefPubMed
37.
Castaneda JA, Lim MJ, Cooper JD, Pearce DA (2008) Immune system irregularities in lysosomal storage disorders. Acta Neuropathol 115(2):159–174CrossRefPubMed
38.
39.
Raghupathy R, Makhseed M, Azizieh F, Omu A, Gupta M, Farhat R (2000) Cytokine production by maternal lymphocytes during normal human pregnancy and in unexplained recurrent spontaneous abortion. Hum Reprod 15(3):713–718CrossRefPubMed
40.
Choi ST, Kim JH, Kang EJ, Lee SW, Park MC, Park YB et al (2008) Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis. Rheumatology (Oxford) 47(12):1775–1779CrossRef
41.
Yoshino M, Watanabe Y, Tokunaga Y, Harada E, Fujii C, Numata S et al (2007) Roles of specific cytokines in bone remodeling and hematopoiesis in Gaucher disease. Pediatr Int : Off J Jpn Pediatr Soc 49(6):959–965CrossRef
42.
Wang KX, Denhardt DT (2008) Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 19(5–6):333–345CrossRefPubMed
43.
Furger KA, Menon RK, Tuck AB, Bramwell VH, Chambers AF (2001) The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 1(5):621–632CrossRefPubMed
44.
Rodrigues LR, Teixeira JA, Schmitt FL, Paulsson M, Lindmark-Mansson H (2007) The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomark Prev: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 16(6):1087–1097CrossRef
45.
Caers J, Gunthert U, De Raeve H, Van Valckenborgh E, Menu E, Van Riet I et al (2006) The involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM model. Br J Haematol 132(4):469–477PubMed
46.
Maetzler W, Berg D, Schalamberidze N, Melms A, Schott K, Mueller JC et al (2007) Osteopontin is elevated in Parkinson’s disease and its absence leads to reduced neurodegeneration in the MPTP model. Neurobiol Dis 25(3):473–482CrossRefPubMed
47.
Maetzler W, Michelis J, Tomiuk J, Melms A, Becker C, Gasser T et al (2009) A single-nucleotide polymorphism of the osteopontin gene may contribute to a susceptibility to Lewy body disease. J Neural Transm 116(5):599–605CrossRefPubMed
48.
Sun Y, Yin XS, Guo H, Han RK, He RD, Chi LJ (2013) Elevated osteopontin levels in mild cognitive impairment and Alzheimer’s disease. Mediat Inflamm 2013:615745CrossRef
49.
50.
Ribner A, Altarescu G, Zimran A, Elstein D (2011) Osteopontin polymorphic susceptibility factor for Parkinson’s disease among patients with Gaucher disease. Mov Disord 26(7):1341–1343CrossRefPubMed
Metadata
Title
Osteopontin: a potential biomarker of Gaucher disease
Authors
Filippo Vairo
Fernanda Sperb-Ludwig
Matheus Wilke
Kristiane Michellin-Tirelli
Cristina Netto
Eurico Camargo Neto
Ida Schwartz
Publication date
01-07-2015
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 7/2015
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-015-2354-7

Other articles of this Issue 7/2015

Annals of Hematology 7/2015 Go to the issue

Original Article

The role of paroxysmal nocturnal hemoglobinuria clones in response to immunosuppressive therapy of patients with severe aplastic anemia

Letter to the Editor

Successful treatment with rivaroxaban of an extended superficial vein thrombosis in a patient with acquired antithrombin deficiency due to Peg-asparaginase treatment

Original Article

Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician’s and patient’s perspectives

Letter to the Editor

Erythropoietin receptor mutation—a rush of blood to the head?

Original Article

Krüppel-like factor 1 mutations and expression of hemoglobins F and A2 in homozygous hemoglobin E syndrome

Letter to the Editor

Myeloproliferative neoplasm in a thalassaemic patient: response to treatment with a JAK inhibitor
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits